drugset / Trial / NCT00950742
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.
NaSingle-groupOpen-labelTreatment
Summary
Study to determine the Maximum Tolerated dose of BIBW 2992 given in combination with Herceptin®
Timeline
- Start
- 2009-08-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 20 mg | Oral |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | Other |